HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.01 per share
Symbol
HRTX on Nasdaq
Shares outstanding
183,255,226
Price per share
$1.30
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
152,658,767
Total reported value
$192,362,843
% of total 13F portfolios
0%
Share change
+21,166,310
Value change
+$22,498,776
Number of holders
171
Price from insider filings
$1.30
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Rubric Capital Management LP 16% -8.9% $37,859,003 +$1,192,086 30,046,828 +3.3% Rubric Capital Management LP 15 Oct 2025
Clearline Capital LP 5.3% $11,655,032 9,712,527 Clearline Capital LP 30 Sep 2025
VANGUARD GROUP INC 4.6% $10,659,328 8,459,784 The Vanguard Group 30 Sep 2025

As of 30 Sep 2025, 171 institutional investors reported holding 152,658,767 shares of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX). This represents 83% of the company’s total 183,255,226 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) together control 73% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Rubric Capital Management LP 16% 29,100,728 +8.9% 0.49% $36,666,917
ADAGE CAPITAL PARTNERS GP, L.L.C. 5.6% 10,239,225 +30% 0.02% $12,901,424
BlackRock, Inc. 5.5% 9,987,460 -1.1% 0% $12,584,200
Clearline Capital LP 5.3% 9,712,527 +1033% 1.1% $12,237,784
Velan Capital Investment Management LP 4.8% 8,753,290 +25% 10% $11,029,145
VANGUARD GROUP INC 4.6% 8,459,784 -0.14% 0% $10,659,328
PALISADE CAPITAL MANAGEMENT, LP 4% 7,327,447 +44% 0.25% $9,232,583
Tejara Capital Ltd 2.5% 4,589,715 +1.6% 3.2% $5,783,041
BAKER BROS. ADVISORS LP 2.3% 4,251,951 0.04% $5,357,458
STATE STREET CORP 2% 3,651,503 +5.5% 0% $4,600,894
GEODE CAPITAL MANAGEMENT, LLC 2% 3,642,982 +2.1% 0% $4,591,019
TANG CAPITAL MANAGEMENT LLC 1.9% 3,450,000 +62% 0.17% $4,347,000
JW Asset Management, LLC 1.8% 3,292,633 +41% 2% $4,148,718
D. E. Shaw & Co., Inc. 1.7% 3,088,492 -3.5% 0% $3,891,500
UBS Group AG 1.6% 2,934,081 -7.9% 0% $3,696,943
Congress Park Capital LLC 1.6% 2,890,157 +27% 1.1% $3,641,598
RENAISSANCE TECHNOLOGIES LLC 1.6% 2,854,999 +6.2% 0% $3,597,299
CITADEL ADVISORS LLC 1.5% 2,708,457 +22% 0% $3,412,656
NEW YORK STATE COMMON RETIREMENT FUND 1.4% 2,576,716 +46% 0% $3,246,662
CITIGROUP INC 1.4% 2,476,529 +4667% 0% $3,120,427
MORGAN STANLEY 1.3% 2,468,041 -11% 0% $3,109,732
AQR CAPITAL MANAGEMENT LLC 1.1% 1,936,689 +3036% 0% $2,440,228
GOLDMAN SACHS GROUP INC 0.72% 1,324,802 +27% 0% $1,669,251
MARSHALL WACE, LLP 0.71% 1,308,861 -55% 0% $1,649,165
JPMORGAN CHASE & CO 0.71% 1,292,444 +36% 0% $1,628,479

Institutional Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 3,407,064 $4,429,494 +$185,462 $1.30 9
2025 Q3 152,658,767 $192,362,843 +$22,498,776 $1.26 171
2025 Q2 131,463,843 $272,131,676 +$12,999,504 $2.07 170
2025 Q1 124,770,231 $274,489,465 +$21,978,995 $2.20 164
2024 Q4 114,942,022 $175,830,362 -$13,145,677 $1.53 161
2024 Q3 121,816,811 $242,421,127 -$29,164,437 $1.99 169
2024 Q2 129,609,462 $453,637,783 +$35,414,242 $3.50 190
2024 Q1 119,262,891 $330,362,772 +$20,426,958 $2.77 157
2023 Q4 41,355 $70,304 $1.70 1
2023 Q3 118,378,841 $121,933,794 +$19,988,838 $1.03 138
2023 Q2 98,643,897 $114,425,879 -$11,693,216 $1.16 142
2023 Q1 100,755,886 $152,139,518 -$16,186,041 $1.51 151
2022 Q4 115,775,434 $289,441,921 -$30,862,540 $2.50 173
2022 Q3 118,392,379 $499,274,230 +$44,245,485 $4.22 173
2022 Q2 112,203,345 $313,031,107 +$4,197,438 $2.79 156
2022 Q1 108,482,196 $620,176,626 -$95,377,953 $5.72 172
2021 Q4 117,045,768 $1,068,170,355 +$79,747,547 $9.13 187
2021 Q3 107,482,163 $1,150,175,758 +$45,432,536 $10.69 192
2021 Q2 103,344,530 $1,604,077,175 +$203,905,328 $15.52 185
2021 Q1 90,513,746 $1,472,519,066 -$13,798,155 $16.21 187
2020 Q4 90,254,547 $1,910,207,883 +$27,916,036 $21.16 176
2020 Q3 90,829,513 $1,346,164,946 +$33,007,846 $14.82 172
2020 Q2 85,644,202 $1,290,698,232 -$48,763,159 $14.71 179
2020 Q1 91,959,265 $1,079,580,715 -$127,638,119 $11.74 179
2019 Q4 98,465,392 $2,312,773,060 +$189,519,484 $23.50 190
2019 Q3 85,809,049 $1,587,681,958 -$39,955,743 $18.50 170
2019 Q2 93,836,833 $1,743,997,239 +$14,297,819 $18.59 168
2019 Q1 86,517,413 $2,114,329,795 +$26,514,308 $24.44 185
2018 Q4 85,265,141 $2,211,182,978 +$96,815,817 $25.94 165
2018 Q3 81,512,376 $2,579,828,136 +$144,171,822 $31.65 186
2018 Q2 76,390,031 $2,955,758,173 +$199,481,826 $38.85 189
2018 Q1 72,532,065 $2,000,910,074 +$345,449,111 $27.60 148
2017 Q4 60,500,377 $1,091,450,861 +$99,723,659 $18.10 120
2017 Q3 63,276,056 $1,021,904,242 -$89,834,807 $16.15 100
2017 Q2 60,725,503 $841,047,934 +$47,458,127 $13.85 99
2017 Q1 62,400,860 $936,042,765 +$300,270,140 $15.00 93
2016 Q4 52,588,774 $688,897,257 +$4,705,623 $13.10 91
2016 Q3 44,918,692 $773,886,939 +$71,898,310 $17.23 86
2016 Q2 46,993,884 $848,220,481 +$17,226,678 $18.05 89
2016 Q1 39,826,627 $756,377,019 -$8,617,590 $18.99 97
2015 Q4 45,438,608 $1,214,308,465 +$41,591,431 $26.70 102
2015 Q3 43,669,930 $1,064,954,157 +$172,451,211 $24.40 100
2015 Q2 35,846,123 $1,116,675,953 +$319,196,524 $31.16 83
2015 Q1 26,289,641 $382,515,043 +$30,830,264 $14.55 64
2014 Q4 24,573,733 $247,206,441 +$2,535,939 $10.06 62
2014 Q3 24,228,148 $201,819,819 -$7,800,476 $8.33 54
2014 Q2 26,504,296 $326,479,299 +$63,311,759 $12.32 65
2014 Q1 16,392,942 $227,849,683 +$222,200,589 $13.91 38